We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report?
Read MoreHide Full Article
A month has gone by since the last earnings report for Iovance Biotherapeutics (IOVA - Free Report) . Shares have lost about 1.4% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Iovance Biotherapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Iovance Incurs Wider-Than-Expected Q1 Loss
Iovance incurred loss of 55 cents per share in first-quarter 2020, wider than the Zacks Consensus Estimate of a loss of 53 cents as well as the year-ago quarter’s loss of 30 cents.
The company did not record any revenues during the quarter.
Quarter in Detail
Research & development (R&D) expenses were $57 million, up 84.5% from the year-ago quarter. The significant increase was due to rise in manufacturing and clinical activities, and cost related to in-licensing of the IOV-3001 IL-2 analog from Novartis.
General and administrative (G&A) expenses increased 52.7% to $13.9 million due to increase in related personnel and higher legal costs.
The company had $251.2 million in cash, cash equivalents, short-term investments and restricted cash compared with $312.5 million as of Dec 31, 2020.
How Have Estimates Been Moving Since Then?
It turns out, estimates review flatlined during the past month.
VGM Scores
Currently, Iovance Biotherapeutics has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Iovance Biotherapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Why Is Iovance Biotherapeutics (IOVA) Down 1.4% Since Last Earnings Report?
A month has gone by since the last earnings report for Iovance Biotherapeutics (IOVA - Free Report) . Shares have lost about 1.4% in that time frame, underperforming the S&P 500.
Will the recent negative trend continue leading up to its next earnings release, or is Iovance Biotherapeutics due for a breakout? Before we dive into how investors and analysts have reacted as of late, let's take a quick look at its most recent earnings report in order to get a better handle on the important drivers.
Iovance Incurs Wider-Than-Expected Q1 Loss
Iovance incurred loss of 55 cents per share in first-quarter 2020, wider than the Zacks Consensus Estimate of a loss of 53 cents as well as the year-ago quarter’s loss of 30 cents.
The company did not record any revenues during the quarter.
Quarter in Detail
Research & development (R&D) expenses were $57 million, up 84.5% from the year-ago quarter. The significant increase was due to rise in manufacturing and clinical activities, and cost related to in-licensing of the IOV-3001 IL-2 analog from Novartis.
General and administrative (G&A) expenses increased 52.7% to $13.9 million due to increase in related personnel and higher legal costs.
The company had $251.2 million in cash, cash equivalents, short-term investments and restricted cash compared with $312.5 million as of Dec 31, 2020.
How Have Estimates Been Moving Since Then?
It turns out, estimates review flatlined during the past month.
VGM Scores
Currently, Iovance Biotherapeutics has a poor Growth Score of F, however its Momentum Score is doing a lot better with an A. However, the stock was allocated a grade of C on the value side, putting it in the middle 20% for this investment strategy.
Overall, the stock has an aggregate VGM Score of D. If you aren't focused on one strategy, this score is the one you should be interested in.
Outlook
Iovance Biotherapeutics has a Zacks Rank #3 (Hold). We expect an in-line return from the stock in the next few months.